Limits...
Continuing to Confront COPD International Patient Survey: Economic Impact of COPD in 12 Countries.

Foo J, Landis SH, Maskell J, Oh YM, van der Molen T, Han MK, Mannino DM, Ichinose M, Punekar Y - PLoS ONE (2016)

Bottom Line: Indirect costs were calculated from work loss values using the Work Productivity and Activity Impairment scale.Combined direct and indirect costs estimated the total societal costs per patient.The annual direct costs of COPD ranged from $504 (South Korea) to $9,981 (USA), with inpatient hospitalisations (5 countries) and home oxygen therapy (3 countries) being the key drivers of direct costs.

View Article: PubMed Central - PubMed

Affiliation: Health Outcomes, GlaxoSmithKline, Uxbridge, United Kingdom.

ABSTRACT

Background: The Continuing to Confront COPD International Patient Survey estimated the prevalence and burden of COPD across 12 countries. Using data from this survey we evaluated the economic impact of COPD.

Methods: This cross-sectional, population-based survey questioned 4,343 subjects aged 40 years and older, fulfilling a case definition of COPD based on self-reported physician diagnosis or symptomatology. Direct cost measures were based on exacerbations of COPD (treated and those requiring emergency department visits and/or hospitalisation), contacts with healthcare professionals, and COPD medications. Indirect costs were calculated from work loss values using the Work Productivity and Activity Impairment scale. Combined direct and indirect costs estimated the total societal costs per patient.

Results: The annual direct costs of COPD ranged from $504 (South Korea) to $9,981 (USA), with inpatient hospitalisations (5 countries) and home oxygen therapy (3 countries) being the key drivers of direct costs. The proportion of patients completely prevented from working due to their COPD ranged from 6% (Italy) to 52% (USA and UK) with 8 countries reporting this to be ≥20%. Total societal costs per patient varied widely from $1,721 (Russia) to $30,826 (USA) but a consistent pattern across countries showed greater costs among those with increased burden of COPD (symptoms, health status and more severe disease) and a greater number of comorbidities.

Conclusions: The economic burden of COPD is considerable across countries, and requires targeted resources to optimise COPD management encompassing the control of symptoms, prevention of exacerbations and effective treatment of comorbidities. Strategies to allow COPD patients to remain in work are important for addressing the substantial wider societal costs.

Show MeSH

Related in: MedlinePlus

Annual societal per patient cost using exchange rates (Nov 2012 to May 2013) and Purchasing Power Parities (2013) (US$): Continuing to Confront COPD International Patient Survey, 2012–13.Abbreviations: USA, United States of America, UK, United Kingdom, NL, Netherlands; SK, South Korea
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4836731&req=5

pone.0152618.g003: Annual societal per patient cost using exchange rates (Nov 2012 to May 2013) and Purchasing Power Parities (2013) (US$): Continuing to Confront COPD International Patient Survey, 2012–13.Abbreviations: USA, United States of America, UK, United Kingdom, NL, Netherlands; SK, South Korea

Mentions: The calculated annual societal per patient cost of COPD varied widely across countries, ranging from $1,721 in Russia to $30,826 in the USA (Fig 2). The indirect cost of COPD exceeded the direct cost in all countries except for France, where indirect costs per patient were $2,277 and direct costs per patient were $3,406. Indirect costs in Brazil, Germany, the UK, the Netherlands and South Korea comprised over 80% of the total societal costs. A sensitivity analysis of total societal costs using purchasing power parities instead of exchange rates demonstrated higher per patient costs of COPD in Mexico, Brazil, Russia, Spain, and South Korea, and similar or slightly lower costs in the remaining countries outside of the USA (Fig 3). However, the order of magnitude of overall societal costs across countries remained largely the same.


Continuing to Confront COPD International Patient Survey: Economic Impact of COPD in 12 Countries.

Foo J, Landis SH, Maskell J, Oh YM, van der Molen T, Han MK, Mannino DM, Ichinose M, Punekar Y - PLoS ONE (2016)

Annual societal per patient cost using exchange rates (Nov 2012 to May 2013) and Purchasing Power Parities (2013) (US$): Continuing to Confront COPD International Patient Survey, 2012–13.Abbreviations: USA, United States of America, UK, United Kingdom, NL, Netherlands; SK, South Korea
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4836731&req=5

pone.0152618.g003: Annual societal per patient cost using exchange rates (Nov 2012 to May 2013) and Purchasing Power Parities (2013) (US$): Continuing to Confront COPD International Patient Survey, 2012–13.Abbreviations: USA, United States of America, UK, United Kingdom, NL, Netherlands; SK, South Korea
Mentions: The calculated annual societal per patient cost of COPD varied widely across countries, ranging from $1,721 in Russia to $30,826 in the USA (Fig 2). The indirect cost of COPD exceeded the direct cost in all countries except for France, where indirect costs per patient were $2,277 and direct costs per patient were $3,406. Indirect costs in Brazil, Germany, the UK, the Netherlands and South Korea comprised over 80% of the total societal costs. A sensitivity analysis of total societal costs using purchasing power parities instead of exchange rates demonstrated higher per patient costs of COPD in Mexico, Brazil, Russia, Spain, and South Korea, and similar or slightly lower costs in the remaining countries outside of the USA (Fig 3). However, the order of magnitude of overall societal costs across countries remained largely the same.

Bottom Line: Indirect costs were calculated from work loss values using the Work Productivity and Activity Impairment scale.Combined direct and indirect costs estimated the total societal costs per patient.The annual direct costs of COPD ranged from $504 (South Korea) to $9,981 (USA), with inpatient hospitalisations (5 countries) and home oxygen therapy (3 countries) being the key drivers of direct costs.

View Article: PubMed Central - PubMed

Affiliation: Health Outcomes, GlaxoSmithKline, Uxbridge, United Kingdom.

ABSTRACT

Background: The Continuing to Confront COPD International Patient Survey estimated the prevalence and burden of COPD across 12 countries. Using data from this survey we evaluated the economic impact of COPD.

Methods: This cross-sectional, population-based survey questioned 4,343 subjects aged 40 years and older, fulfilling a case definition of COPD based on self-reported physician diagnosis or symptomatology. Direct cost measures were based on exacerbations of COPD (treated and those requiring emergency department visits and/or hospitalisation), contacts with healthcare professionals, and COPD medications. Indirect costs were calculated from work loss values using the Work Productivity and Activity Impairment scale. Combined direct and indirect costs estimated the total societal costs per patient.

Results: The annual direct costs of COPD ranged from $504 (South Korea) to $9,981 (USA), with inpatient hospitalisations (5 countries) and home oxygen therapy (3 countries) being the key drivers of direct costs. The proportion of patients completely prevented from working due to their COPD ranged from 6% (Italy) to 52% (USA and UK) with 8 countries reporting this to be ≥20%. Total societal costs per patient varied widely from $1,721 (Russia) to $30,826 (USA) but a consistent pattern across countries showed greater costs among those with increased burden of COPD (symptoms, health status and more severe disease) and a greater number of comorbidities.

Conclusions: The economic burden of COPD is considerable across countries, and requires targeted resources to optimise COPD management encompassing the control of symptoms, prevention of exacerbations and effective treatment of comorbidities. Strategies to allow COPD patients to remain in work are important for addressing the substantial wider societal costs.

Show MeSH
Related in: MedlinePlus